The US Food and Drug Administration has announced that while COVID-19 travel restrictions will continue to delay on-site preapproval inspections, sponsors of new drugs that have received a complete response letter can expect to be inspected within six months of responding to the CRL.
Firms That Get Complete Response Letters Might Get Inspected By US FDA Six Months After Replies
Pandemic Continuing to Make Travel Difficult For Inspectors
While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.
More from Manufacturing
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.